Previous 10 | Next 10 |
Karyopharm to Host Virtual Investor Day on December 8, 2021 PR Newswire NEWTON, Mass. , Dec. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will ...
During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm Therapeutics (KPTI +1.1%), Esperion Therapeutics (E...
Karyopharm to Participate at Jefferies London Healthcare Conference PR Newswire NEWTON, Mass. , Nov. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...
The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Karyopharm Therapeutics Inc. 2021 Q3 - Results - Earnings Call Presentation
Should Investors Be Buying These Top Health Care Stocks Today? Health care stocks , among other things, could be in focus in the stock market today . Namely, this would be thanks to the Biden administration’s latest COVID-19 vaccine mandate. In detail, U.S. employers ...
Karyopharm Therapeutics (KPTI +0.4%) is rising on new data from a phase 2 study selinexor in patients with myelofibrosis (MF) who were resistant or intolerant to JAK inhibitors. MF is a type of bone marrow cancer that disrupts the body's ability to produce normal blood cells. The main go...
Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition -- 33% of Patients Who Received at Least 24 Weeks of Selinexor Treatment Achieved a Response, Defined ...
Image source: The Motley Fool. Karyopharm Therapeutics inc (NASDAQ: KPTI) Q3 2021 Earnings Call Nov 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics inc (KPTI) Q3 2021 Earnings Call Transcr...
Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +58%. iRhythm Technologies IRTC +50%. R. R. Donnelley & Sons RRD +37%. Karyopharm Therapeutics KPTI +28%. Veritiv VRTV +27%. Criteo CRTO +27%. BlueLinx Holdings BXC +26%. Onion Global (NYSE:OG) +26%. Bed Bath &...
Karyopharm Therapeutics Inc. (KPTI) Q3 2021 Earnings Conference Call November 03, 2021 08:30 AM ET Company Participants Jason Finkelstein - Argot Partners Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Senior Vice President-Sales & Commercial Operations Jatin Sh...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...